Paradigm

Paradigm is a clinical trial technology company that helps healthcare providers and clinical trial operators to identify and recruit patients for clinical trials. The company assists the patient recruitment process by integrating healthcare electronic health records with clinical trial recruitment systems. This integration allows the filtration of patients to create more representative samples in clinical trials while enabling the collaboration between healthcare providers and clinical trial operators. Paradigm aims to improve its data collection process through automation and AI, making it easier for physicians to maintain records. The company was conceived by Arch Venture Partners and co-incubated with General Catalyst.

The company operates on a B2B basis, where the company does not charge healthcare companies for using the platform; instead, it aims to charge pharmaceutical companies that use the platform to find patients for clinical trials.

In January 2023, the company acquired Deep Lens, a clinical trial platform provider that assists with oncology patient recruitment. Through the acquisition, Deep Lens’ operations and patient recruitment platform were incorporated into Paradigm’s and the company ceased independent operations. The terms of the acquisition were not disclosed.

Key customers and partnerships

In October 2023 the company partnered with Bristol Myers Squibb to build a end-to-end clinical trial operating that offered features covering trial design, recruitment, and data collection. Through the partnership, Paradigm would create this platform for Bristol Myers Squibb to initially use for oncology-related clinical trials, expanding its use later for use in other therapeutic fields.

In August 2024, Paradigm partnered with Fujitsu, a global technology company, to improve clinical trials and address drug loss in Japan. The partnership aimed to streamline medical institution data collection and processing, accelerate clinical trial planning, and attract global trials to Japan. Through the partnership Fujitsu began leveraging its Healthy Living Platform, Kozuchi AI service, and a new Patient-centric Clinical Trials service using a proprietary LLM to automate document creation. The collaboration sought to modernize clinical trials in Japan, increase patient accrual, decrease drug development timelines and costs, and establish Japan as a key player in the global clinical trials ecosystem. Fujitsu aimed to secure JPY 20 billion (USD 138 million) in revenue by fiscal 2030 through these efforts.

In September 2024, Paradigm partnered with the Florida Cancer Specialists & Research Institute (FCS) to expand patient access to clinical trials using Paradigm's technology platform. The partnership aimed to streamline clinical trial planning, recruitment, and execution across FCS' 33 research locations. Paradigm's AI-enabled platform allowed FCS to screen all patients for trial eligibility, potentially increasing participation in innovative cancer treatments. The collaboration was expected to benefit patients by providing more opportunities to access cutting-edge therapies closer to home.

Also in September 2024, Paradigm partnered with Sheba Medical Center, Israel's largest hospital, and its innovation arm, ARC Innovation, to establish a global network for clinical research. The collaboration aimed to revolutionize clinical trials by utilizing Paradigm's AI-driven platform to automate processes, enhance site selection, and improve patient recruitment and retention.